- Agios says adios to sickle cell program over lackluster phase 2 dataA phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell disease, leading the company to ax an indication for t…Fierce Biotech · 7d ago↗ source
- Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’Novartis has dropped a phase 2-stage radioligand therapy after the candidate disappointed in the clinic.Fierce Biotech · 7d ago↗ source
- Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assetsLupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit targets purs…